Scarica l'app Stockscreener
1.29
7.50%
0.09
Dopo l'orario di chiusura:
1.29
Precedente Chiudi:
$1.20
Aprire:
$1.21
Volume 24 ore:
400.65K
Relative Volume:
1.21
Capitalizzazione di mercato:
$67.13M
Reddito:
-
Utile/perdita netta:
$-121.83M
Rapporto P/E:
-0.5945
EPS:
-2.17
Flusso di cassa netto:
$-110.58M
1 W Prestazione:
-9.79%
1M Prestazione:
-35.50%
6M Prestazione:
-66.58%
1 anno Prestazione:
-43.17%
Intervallo 1D:
$1.18
$1.32
Intervallo di 1 settimana:
$1.10
$1.4198
Portata 52W:
$1.10
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
PRLD stock touches 52-week low at $1.32 amid market challenges - Investing.com Australia
Prelude Therapeutics’ (PRLD) Buy Rating Reiterated at HC Wainwright - Defense World
PRLD stock touches 52-week low at $1.32 amid market challenges By Investing.com - Investing.com South Africa
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts - Investing.com Nigeria
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts By Investing.com - Investing.com South Africa
Prelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC Wainwright - MarketBeat
Prelude Therapeutics price target lowered to $1 from $3 at Barclays - Yahoo Finance
Prelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International Symposium - MyChesCo
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium - Yahoo Finance
PRLD stock touches 52-week low at $1.65 amid market challenges - Investing.com India
PRLD stock touches 52-week low at $1.65 amid market challenges By Investing.com - Investing.com South Africa
Deal Watch: Lilly Turns To Oblique For Antibody Discovery - Scrip
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Sees Significant Decline in Short Interest - MarketBeat
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MyChesCo
Prelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona Symposium - MyChesCo
Prelude Therapeutics shares updates on cancer drug trials By Investing.com - Investing.com Canada
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium - Yahoo Finance
Wall Street today: US stocks trade higher as investors re-evaluate big Fed rate cut potential, Intel Corp. gains 1.83% - MSN
Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Increases By 37.0% - MarketBeat
Invesco S&P SmallCap Materials ETF (NASDAQ:PSCM) Short Interest Up 22.6% in September - Defense World
RF Acquisition Corp. (NASDAQ:RFAC) Short Interest Update - Defense World
Squarepoint Ops LLC Grows Stock Holdings in Teleflex Incorporated (NYSE:TFX) - Defense World
Axa S.A. Acquires 1,964 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) - Defense World
Employees Retirement System of Texas Makes New Investment in Nova Ltd. (NASDAQ:NVMI) - Defense World
FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology - MyChesCo
Firstsource Acquires Ascensos - MENAFN.COM
Firstsource acquires UK-based Ascensos for $56 million - The Economic Times
Angel Capital weaves passage to glory in Guineas Prelude - Horse Betting
19 Sundance Movies to Watch Before Seeing These Filmmakers’ New Fall 2024 Releases - Sundance Institute
First Taste: At Prelude, Southern-inspired flavors get the fine-dining spotlight. - 7x7
Prelude Therapeutics (NASDAQ:PRLD) Upgraded to Strong-Buy by HC Wainwright - MarketBeat
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MyChesCo
Data clang on Street for Prelude but SMARCA2 overtures continue - BioWorld Online
Healthy Upside Potential: Prelude Therapeutics Inc (PRLD) - SETE News
Prelude Therapeutics Inc (PRLD) deserves closer scrutiny - US Post News
Prelude Therapeutics (NASDAQ:PRLD) Receives “Market Outperform” Rating from JMP Securities - Defense World
A Closer Look at Prelude Therapeutics Inc (PRLD) Stock Gains - The InvestChronicle
Glioblastoma Treatment Drugs, Pipeline Insights, Emerging Therapies, and Companies 2024 - openPR
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate - Simply Wall St
Ratios Reveal: Breaking Down Prelude Therapeutics Inc (PRLD)’s Financial Health - The Dwinnex
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment - MyChesCo
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - Yahoo Finance
Prelude reports positive early results for cancer drug PRT3789 - Investing.com
Prelude Therapeutics (NASDAQ:PRLD) Receives Neutral Rating from HC Wainwright - Defense World
Prelude Therapeutics Unveils Promising Data on PRT3789 at ESMO Congress 2024 - MyChesCo
Prelude Therapeutics' (PRLD) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 2.3% - MarketBeat
Prelude reports safety of new cancer drug at ESMO Congress By Investing.com - Investing.com Canada
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 - Yahoo Finance
SFA Therapeutics Appoints Dr. Ananda Gubbi as Director of Biostatistics to Enhance Drug Development - MyChesCo
Prelude Therapeutics, Merck Enter Clinical Collaboration - Contract Pharma
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):